Unusual 11 Mid-Day Movers 12/1: (HTBX) (ARDM) (EXPR) Higher; (SGY) (TLYS) (CBK) Lower
- Dollar lower, stocks flat as caution creeps in ahead of Trump inauguration
- General Electric (GE) Reports In-Line Q4 EPS
- Procter & Gamble (PG) Tops Q2 EPS by 2c
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Aradigm Corporation (Nasdaq: ARDM) 57.5% LOWER; announced top-line results from its two Phase 3 clinical trials (ORBIT-3 and ORBIT-4) evaluating the safety and efficacy of Pulmaquin®, the Company’s investigational proprietary formulation of once daily ciprofloxacin for inhalation, in patients with non-cystic fibrosis bronchiectasis (“non-CF BE”) with chronic lung infections with Pseudomonas aeruginosa (P. aeruginosa).
Stone Energy (NYSE: SGY) 56.7% HIGHER; surging on volume today. Short interest was last at about 1.49 million shares, or 32 percent of float.
Tilly's, Inc. (NYSE: TLYS) 35.3% HIGHER; reported Q3 EPS of $0.22, $0.11 better than the analyst estimate of $0.11. Revenue for the quarter came in at $152.1 million versus the consensus estimate of $143 million. Tilly's, Inc. sees Q4 2016 EPS of $0.15-$0.20, versus the consensus of $0.18.
Christopher & Banks (NYSE: CBK) 20.4% HIGHER; reported Q3 EPS of $0.09, $0.04 better than the analyst estimate of $0.05. Revenue for the quarter came in at $106.7 million versus the consensus estimate of $104.66 million. Christopher & Banks sees Q4 2016 revenue of $93-97 million, versus the consensus of $99.6 million.
Express (NYSE: EXPR) 21.2% LOWER; reported Q3 EPS of $0.15, $0.02 better than the analyst estimate of $0.13. Revenue for the quarter came in at $506.1 million versus the consensus estimate of $498.75 million. Comps fell 8 percent, versus a drop of 9.9 percent expected by the Street. Express sees FY2016 EPS of $0.78-$0.82, versus the consensus of $1.05.
bluebird bio, Inc. (Nasdaq: BLUE) 18.3% HIGHER; presented strong interim data from its ongoing Phase 1 clinical study of bb2121, the company’s investigational anti-BCMA CAR T cell product candidate in patients with relapsed/refractory multiple myeloma.
CLARCOR Inc. (NYSE: CLC) 16.8% HIGHER; Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. Under the terms of the agreement, Parker will purchase all of the outstanding shares of CLARCOR for $83.00 per share in cash.
PhaseRx, Inc. (Nasdaq: PZRX) 16.6% LOWER; continuing to pullback following a 150 percent gain last Monday.
Skechers USA (NYSE: SKX) 15.5% HIGHER; CEO Robert Greenberg bought 500,000 share from 11/28 - 11/29 at prices from $21.18 - $21.75 per share.
FuelCell Energy, Inc. (Nasdaq: FCEL) 11.1% LOWER; announced a business restructuring to reduce costs and align production levels with current levels of demand in a manner that is consistent with the Company’s long-term strategic plan. Total revenues for the fourth quarter of 2016 are expected to be in the range of $23 - $25 million, with total fiscal 2016 revenue in the range of $107 - $109 million. (NOTE: The Street sees Q4 revenue of $52.3 million and FY16 revenue of $136.0 million.)
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M
- Accenture (ACN) to Acquire Seabury Group's Corporate Advisory and Aviation Consulting Business; Terms Not Disclosed
- Bats Global Market (BATS) Stockholders Approve Merger Agreement with CBOE (CBOE)